You are here

Flexion Therapeutics Announces New In Vitro Data Showing Protective Effects of Triamcinolone Acetonide on Cartilage

BURLINGTON, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced results from a preclinical study which showed that triamcinolone acetonide (TA) had protective effects on inflamed and/or injured cartilage. Led by Professor Alan Grodzinsky, Sc.D., Director of the Center for Biomedical Engineering at the Massachusetts Institute of Technology (MIT), the study utilized an established in vitro model1 with cartilage explants subjected to inflammatory cytokines and a single impact mechanical injury. This in vitro model was used to assess the effects of a range of doses of TA on cartilage tissue explants during a 1-week treatment regimen.
Thursday, February 21, 2019 - 16:30